Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07178912CT.gov Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | — | Not Yet Recruiting | — | — | — |
NCT07387926CT.gov Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | — | Not Yet Recruiting | — | — | — |
NCT07454226CT.gov ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | — | Recruiting | — | — | — |
NCT07227584CT.gov ALL Backbone in AYAs | — | Not Yet Recruiting | — | — | — |
NCT05521087CT.gov A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | — | Withdrawn | — | — | — |
NCT07301138CT.gov BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | — | Not Yet Recruiting | — | — | — |
NCT06930105CT.gov Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL | — | Not Yet Recruiting | — | — | — |
NCT07152041CT.gov Newly-diagnosed Pediatric Ph-positive B-ALL Protocol | — | Recruiting | — | — | — |
NCT06533748CT.gov Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | — | Recruiting | — | — | — |
NCT06207123CT.gov A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | — | Recruiting | — | — | — |
Show 84 more trialsShow fewer
NCT05827549CT.gov Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT04845035CT.gov Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | — | Withdrawn | — | — | — |
NCT06175702CT.gov Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | — | Not Yet Recruiting | — | — | — |
NCT05848687CT.gov TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | — | Recruiting | — | — | — |
NCT05959720CT.gov Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | — | Recruiting | — | — | — |
NCT06051409CT.gov A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | — | Recruiting | — | — | — |
NCT05748171CT.gov A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | — | Recruiting | — | — | — |
NCT05581030CT.gov CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | — | Recruiting | — | — | — |
NCT05292664CT.gov Venetoclax Basket Trial for High Risk Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05192889CT.gov Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | — | Active Not Recruiting | — | — | — |
NCT05326516CT.gov A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | — | Completed | — | — | — |
NCT04752163CT.gov DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT04747912CT.gov Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | — | Recruiting | — | — | — |
NCT03851081CT.gov Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia | — | Withdrawn | — | — | — |
NCT04307576CT.gov A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03860844CT.gov Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03571321CT.gov Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT03349281CT.gov Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | — | Completed | — | — | — |
NCT03519984CT.gov EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | — | Terminated | — | — | — |
NCT03147612CT.gov Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT03136146CT.gov Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | — | Recruiting | — | — | — |
NCT03286634CT.gov ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | — | Active Not Recruiting | — | — | — |
NCT03117751CT.gov Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02879643CT.gov Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy | — | Completed | — | — | — |
NCT02518750CT.gov Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | — | Terminated | — | — | — |
NCT02881086CT.gov Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | — | Completed | — | — | — |
NCT03553238CT.gov Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | — | Unknown | — | — | — |
NCT03564704CT.gov Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | — | Unknown | — | — | — |
NCT02553460CT.gov Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | — | Active Not Recruiting | — | — | — |
NCT02393859CT.gov Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT02523976CT.gov Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02535806CT.gov Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | — | Terminated | — | — | — |
NCT02143414CT.gov Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02404220CT.gov Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | — | Terminated | — | — | — |
NCT02419755CT.gov Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | — | Terminated | — | — | — |
NCT02303821CT.gov Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02451774CT.gov Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction | — | Unknown | — | — | — |
NCT02228772CT.gov Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | — | Completed | — | — | — |
NCT02003222CT.gov Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02083250CT.gov Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT02043587CT.gov Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | — | Terminated | — | — | — |
NCT01887587CT.gov Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | — | Terminated | — | — | — |
NCT01439347CT.gov A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL | — | Terminated | — | — | — |
NCT01540812CT.gov Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS | — | Completed | — | — | — |
NCT01483690CT.gov A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | — | Terminated | — | — | — |
NCT01523977CT.gov Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | — | Completed | — | — | — |
NCT01424982CT.gov Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01324180CT.gov Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT01312818CT.gov Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | — | Terminated | — | — | — |
NCT01186328CT.gov EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | — | Terminated | — | — | — |
NCT01184885CT.gov A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | — | Completed | — | — | — |
NCT01004497CT.gov First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | — | Completed | — | — | — |
NCT00968253CT.gov RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00973752CT.gov Treatment of Older Adults With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00928200CT.gov Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | — | Terminated | — | — | — |
NCT00905034CT.gov Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage | — | Completed | — | — | — |
NCT02894645CT.gov Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | — | Unknown | — | — | — |
NCT00846703CT.gov The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia | — | Unknown | — | — | — |
NCT00549848CT.gov Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00495079CT.gov Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00476190CT.gov ALL Adult Consortium Trial: Adult ALL Trial | — | Completed | — | — | — |
NCT00390793CT.gov Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | — | Completed | — | — | — |
NCT00440726CT.gov Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT00774332CT.gov A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL | — | Unknown | — | — | — |
NCT00313079CT.gov Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00763763CT.gov Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive | — | Completed | — | — | — |
NCT00313053CT.gov Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT00184041CT.gov Intensified Post Remission Therapy Containing PEG-Asparaginase | — | Completed | — | — | — |
NCT00186875CT.gov Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00222612CT.gov Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 | — | Unknown | — | — | — |
NCT00890656CT.gov Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | — | Completed | — | — | — |
NCT00853008CT.gov Treatment of High Risk Adult Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00671658CT.gov Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00131053CT.gov Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) | — | Unknown | — | — | — |
NCT00130195CT.gov Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT00136435CT.gov A Study in Adults With Untreated Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00176462CT.gov CINJALL: Treatment for Children With Acute Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00165178CT.gov Treatment of Acute Lymphoblastic Leukemia in Children | — | Completed | — | — | — |
NCT00137111CT.gov Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00526305CT.gov LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | — | Completed | — | — | — |
NCT00187005CT.gov Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT00187083CT.gov A Study of Children With Refractory or Relapsed ALL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | M.D. Anderson Cancer Center | Approved | BB · 70 |
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Equine Atg | Instituto Nacional de Cancer, Brazil | P3 | BBB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BBB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P4 | BB |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Methotrexate | Princess Maxima Center for Pediatric Oncology | P4 | BB |
| Daunomycin | PETHEMA Foundation | P4 | BB |
+42 more in the Acute Lymphoblastic Leukemia cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterBBB
- Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineBBB
- Equine AtgInstituto Nacional de Cancer, BrazilBBB
- Thioguanine AnhydrousSt. Jude Children's Research HospitalBBB
- Mercaptopurine AnhydrousDana-Farber Cancer InstituteBB
Citation
Floatz Terminal. (+)-Vincristine in Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →